Member Info for oilheadgame

something is up, what is happening

Why is it a big news....this will take few years to do the study....
Agl device has been used for many testing and research.
Not any different

Everybody do one
You lot should be thankful someone wants it for 170 now given the sp is at 117p

mine is getting sold for 100million mcap is 14million
you cant write this!!!

LOT OF PEOPLE IN NICE PROFIT HERE!!
TIME TO CASH!!

now nobody can sell a singel share.
was this is pump to get insiders out before fda delay?

zebbo,

i most defo got spiked :(

FML

Can I please join the telegram group

Is the edingborough study directly related to angle or a similar product?

J Bash , that moron cost me and other money with his BS price action commentary.

Downbut..should be OUT....keep to your vile commentary to yourself. look at yourself in the mirror and keep talking to yourself about your thoughts on share price and what the RNS means to you..dikwad.

nobody cares....

and you need to mind your own darn business!

if asos tickles your bits, then you need to fk off there!

its called manipulation!!!
next set of numbers will be good. maybe not the outlook.
market has priced this badly for failure!!!
theyve got market share, theyve invested in infrastrucuture and american storage!
so....dyor

as much as i hate it relax pal. Lot of people have been waiting for years. Some have moved on. But nobody can question the assets. Market believes the deal is nearly done but dont trust it until they see it in paper!
already ARS have been fooled once!
This is easy 5p on news!

Fking FDA busy approving civic vaccine for babies than saving cancer.

Boo is the most shorted stock now
Not thg

Look at you worms dapping each other with 86p average.
Take a moment for lot of investors with 200p plus average. There is a lot of them

£225k sell or buy?

"Operating cash costs (TCC) guidance is under review given significant changes in prices for certain key materials and equipment as well as exchange rate volatility. The Company has completed the review of non-sustaining development project schedules and budgets. The primary objective of this review was risk assessment against the backdrop of current sanctions, including those self-imposed by Polymetal's commercial counterparties. The key decisions taken are listed below with the updated CAPEX and AISC guidance to be provided at Capital Markets Day on April 25. "

RNS extract
"POX-2 is expected to experience 3-6 month slippage from the original schedule mostly due to logistical challenges. Early-stage projects (Veduga, Mayskoye backfill, Maminskoye) are delayed by one year. Pacific POX project has been suspended indefinitely with studies under way to potentially re-site the facility in Kazakhstan. Brownfield exploration schedule and volumes remain unchanged. Greenfield exploration budgets were reduced by 50% (mostly affecting junior JVs)."